Greg Rossi, Ph.D., is the Senior Vice President responsible for the Oncology Business Unit in Europe and Canada at AstraZeneca. He received his doctorate in Biochemical Engineering from University College London (UCL) and has worked since then in the biotechnology/pharmaceutical industry in the clinical development and commercialisation of oncology therapeutics.

Over the last 25 years, Greg has worked in a number of national (US and UK), regional (Europe) and global roles for Amgen, Genentech, Roche and finally AstraZeneca. Before taking over the management of the Europe and Canada oncology business at AstraZeneca, Greg was responsible for leading the global DNA damage response (DDR) portfolio as well as the global Immuno-Oncology franchise.